title: [Follow-up study on the clinical characteristics and treatment effect of the different types of Guillain-Barré syndrome in children].
abstract: OBJECTIVE
  To study the clinical characteristics and effects of immunoglobulin treatment in children with the different types of Guillain-Barré syndrome (GBS).
  
  
  METHODS
  Data of 108 patients hospitalized for GBS were retrospectively analyzed; 75 cases in this group were given acute high dose of gamma globulin (IVIG) 400 mg/(kg·d) intravenously for 5 d. Clinical and electrophysiological data and information on treatment and recovery of the children were collected during the follow-up and were analyzed.
  
  
  RESULTS
  According to the clinical and electrophysiologic findings, 32 patients manifested acute inflammatory demyelinating polyradiculoneuropathy (AIDP), 34 had acute motor axonal neuropathy (AMAN), 3 had acute motor and sensory axonal neuropathy (AMSAN), 4 were inexcitable, 2 were unclassified. The clinical progress of the AMAN was faster than the AIDP group. Except for sensory nerve involvement, there was no significant difference in the clinical feature and severity. The mean time of the muscle strength began to recover was (5.59±3.63) days in the AIDP group and (7.21±4.68) days in the AMAN group after IVIG treatment. The time of the AIDP group was shorter than the AMAN group, but the difference was not statistically significant (t=-1.5702, P>0.05). The mean time of the muscle strength increased one grade was (8.88±4.39) days in the AIDP group and (12.67±8.35) days in the AMAN group. The difference was statistically significant (t=-2.3689, P<0.05). No patients in this group died. Follow-up data showed that the complete recovery time was not significantly different (t=0.2041, P>0.05).
  
  
  CONCLUSIONS
  The clinical progress of the AMAN was faster than the AIDP group. Besides sensory nerve involvement, there was no significant difference in the clinical feature and severity. The AIDP group's clinical recovery was faster than AMAN's after the immunoglobulin treatment. The two groups were not significantly different in long-term prognosis.
authors.affiliation: Department of Neurology and Rehabilitation, Beijing Children's Hospital Affiliated to Capital Medical University, Beijing 100045, China.
authors.forename: Xiao-hui
authors.initials: XH
authors.lastname: Wang
authors.forename: Li-ping
authors.initials: LP
authors.lastname: Zou
authors.forename: Hu-sheng
authors.initials: HS
authors.lastname: Wu
authors.forename: Fang
authors.initials: F
authors.lastname: Fang
authors.forename: Jun-lan
authors.initials: JL
authors.lastname: Lü
authors.forename: Jing
authors.initials: J
authors.lastname: Xiao
authors.forename: Chang-hong
authors.initials: CH
authors.lastname: Ding
authors.forename: Chun-hong
authors.initials: CH
authors.lastname: Chen
authors.forename: Xu
authors.initials: X
authors.lastname: Wang
authors.forename: Hong
authors.initials: H
authors.lastname: Jin
authors.forename: Wen-min
authors.initials: WM
authors.lastname: Zhou
authors.forename: Fu-yu
authors.initials: FY
authors.lastname: Cai
mesh_terms: D000293:Adolescent; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D020275:Guillain-Barre Syndrome / Q000145:classification / Q000175:diagnosis* / Q000628:therapy*; D006801:Humans; D007223:Infant; D008297:Male; D011379:Prognosis; D012189:Retrospective Studies